Dianthus Therapeutics, Inc. /DE/ Logo

Dianthus Therapeutics, Inc. /DE/

Developing selective antibody therapies for severe autoimmune diseases.

DNTH | US

Overview

Corporate Details

ISIN(s):
US2528281080 (+1 more)
LEI:
Country:
United States of America
Address:
7 TIMES SQUARE, 10036 NEW YORK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies for severe autoimmune diseases. The company focuses on designing and engineering potentially best-in-class monoclonal antibodies with improved potency, high selectivity, and extended half-lives. Its lead candidate, claseprubart (DNTH103), is an antibody that selectively targets the active C1s complement protein. The pipeline also includes DNTH212, a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation. Dianthus's therapeutic approach aims to enable less frequent and more convenient self-administered subcutaneous injections, with the goal of improving clinical outcomes and quality of life for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dianthus Therapeutics, Inc. /DE/ filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dianthus Therapeutics, Inc. /DE/

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dianthus Therapeutics, Inc. /DE/ via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
Karyopharm Therapeutics Inc. Logo
Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.
United States of America KPTI
KAZIA THERAPEUTICS LTD Logo
Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.
United States of America KZIA
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan 4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland KNRS
Kiniksa Pharmaceuticals International, plc Logo
Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.
United States of America KNSA

Talk to a Data Expert

Have a question? We'll get back to you promptly.